Latest filing published 05 Sept 2023 for Alaunos Therapeutics, Inc., €8,800.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Kevin S. Boyle Sr.: trading record in brief
Kevin S. Boyle Sr. is a declared insider of Alaunos Therapeutics, Inc. (chief executive), with filings sourced from SEC (Form 4). Over a trading history stretching from 30 August 2021 to 1 September 2023, the count stands at 5 filings.
The open-market side counts 2 purchases for €12k alongside 1 sale for €8,800. Taken together, the purchases exceed the sales by €3,562. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 2 share grants. In 2023 alone, the filings show no purchases and 1 sale.
The newest entry dates from 5 September 2023: an open-market sale of €8,800, in Alaunos Therapeutics, Inc. The most recent open-market purchase was published on 17 November 2021, 1,817 days ago. The median gap between a trade and its publication by SEC (Form 4) is 1 day. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Kevin S. Boyle Sr.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 68,014 shares@ US$0.140316.3% of flowCommon StockSEC:0000950170-23-046504:0
- 18,750 shares@ US$2.4183.7% of flowCommon StockSEC:0000899243-22-030186:0
- 884 shares@ US$1.40100.0% of flowCommon StockSEC:0001209191-21-065138:0Canonical exit: 14 Feb 2022 (T+90)
- 875,000 shares0Common StockSEC:0001209191-21-054089:0
4 of 4 declarations